Know Cancer

or
forgot password

A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects


Phase 2
3 Years
11 Years
Not Enrolling
Both
Warts

Thank you

Trial Information

A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects


Inclusion Criteria:



- Diagnosis of common warts

- Ages between 3 to 11

Exclusion Criteria:

- Other types of wart(s), ie. plantar

- Currently participating in another clinical study

- Chronic viral hepatitis B or C

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment

Outcome Measure:

Clearance of treated wart(s)

Authority:

United States: Food and Drug Administration

Study ID:

1535-RESI

NCT ID:

NCT00116675

Start Date:

March 2005

Completion Date:

April 2006

Related Keywords:

  • Warts
  • Common Wart(s)
  • Pediatric
  • Wart(s)
  • Children
  • 3M Pharmaceuticals
  • Resiquimod
  • Warts

Name

Location

Dartmouth-Hitchcock Medical CenterLebanon, New Hampshire  03756
Children's Clinic of Jonesboro, PAJonesboro, Arkansas  72401
University of California - San FranciscoSan Francisco, California  94143
Longmont Clinic/Longmont Medical Research NetworkLongmont, Colorado  80501
Mercy Health ResearchSt. Louis, Missouri  63141
Rhode Island Hospital - Jane Brown BuildingProvidence, Rhode Island  02903
DermResearch, Inc.Austin, Texas  78759
Alpine PediatricsPleasant Grove, Utah  84062
Walla Walla ClinicWalla Walla, Washington  99362
Advanced HealthcareMilwaukee, Wisconsin  53209